Tenoxicam

Modify Date: 2024-01-02 20:20:09

Tenoxicam Structure
Tenoxicam structure
 Common Name Tenoxicam
CAS Number 59804-37-4 Molecular Weight 337.374
Density 1.7±0.1 g/cm3 Boiling Point N/A
Molecular Formula C13H11N3O4S2 Melting Point 209-2130ºC
MSDS Chinese USA Flash Point N/A
Symbol GHS06
GHS06		 Signal Word Danger

 Use of Tenoxicam


Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties.Target: COXTenoxicam is a non-steroidal anti-inflammatory drug (NSAID). Tenoxicam-treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH-Px enzyme activities, and MDA levels were unchanged from baseline. Tenoxicam may have antioxidant effects, and it may reduce nitrite levels, indicating an alteration of NO pathways [1]. Tenoxicam was administered intraperitoneally immediately after BCAO. Histological analyses show that ischemia produced significant striatal as well as hippocampal lesions which were reversed by the Tenoxicam treatment. Tenoxicam also significantly reduced, to control levels, the increased myeloperoxidase activity in hippocampus homogenates observed after ischemia [2].

 Names

Name tenoxicam
Synonym More Synonyms

 Tenoxicam Biological Activity

Description Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties.Target: COXTenoxicam is a non-steroidal anti-inflammatory drug (NSAID). Tenoxicam-treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH-Px enzyme activities, and MDA levels were unchanged from baseline. Tenoxicam may have antioxidant effects, and it may reduce nitrite levels, indicating an alteration of NO pathways [1]. Tenoxicam was administered intraperitoneally immediately after BCAO. Histological analyses show that ischemia produced significant striatal as well as hippocampal lesions which were reversed by the Tenoxicam treatment. Tenoxicam also significantly reduced, to control levels, the increased myeloperoxidase activity in hippocampus homogenates observed after ischemia [2].
Related Catalog
Target

COX-1

COX-2

References

[1]. Ozgocmen, S., et al., In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci, 2005. 35(2): p. 137-43.

[2]. Galvao, R.I., et al., Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res, 2005. 30(1): p. 39-46.

 Chemical & Physical Properties

Density 1.7±0.1 g/cm3
Melting Point 209-2130ºC
Molecular Formula C13H11N3O4S2
Molecular Weight 337.374
Exact Mass 337.019104
PSA 136.22000
LogP 1.52
Index of Refraction 1.741
Storage condition -20°C Freezer
Water Solubility Practically insoluble in water, sparingly soluble in methylene chloride, very slightly soluble in anhydrous ethanol. It dissolves in solutions of acids and alkalis.

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XJ9095060
CHEMICAL NAME :
2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide
CAS REGISTRY NUMBER :
59804-37-4
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C13-H11-N3-O4-S2
MOLECULAR WEIGHT :
337.39

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
79 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
234 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - lacrimation Behavioral - somnolence (general depressed activity) Behavioral - ataxia
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
186 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - lacrimation Behavioral - somnolence (general depressed activity) Behavioral - ataxia
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
297 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
446 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
449 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>128 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 18,1030,1987

 Safety Information

Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H301-H311-H331
Precautionary Statements P261-P280-P301 + P310-P311
Personal Protective Equipment Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes T:Toxic
Risk Phrases R23/24/25
Safety Phrases S36/37/39-S45
RIDADR UN 2811
WGK Germany 2
RTECS XJ9095060
HS Code 2934999090

 Customs

HS Code 2934999090
Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Articles36

More Articles
Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.

Arch. Pharm. Res. 38 , 801-12, (2015)

The objective of this study was to improve the dissolution and subsequently the therapeutic efficacy of poorly water soluble BCS class-II drugs meloxicam and tenoxicam, by lipid semi solid matrix (SSM...

[Turbidimetric determination of tenoxicam using molybdophosphoric acid].

Rev. Med. Chir. Soc. Med. Nat. Iasi. 114(1) , 249-54, (2010)

A turbidimetric method was developed for tenoxicam quantification using the complexing reaction with molybdophosphoric acid in hydrochloric acid medium; the complex has a maximum of absorbance at 369 ...

Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs).

Scand. J. Rheumatol. Suppl. 80 , 86-9, (1989)

Investigations have shown that elderly patients have an increased sensitivity to the effects of non-steroidal anti-inflammatory drugs (NSAIDs) with a concomitant higher frequency of side-effects. Seve...

 Synonyms

Apo-Tenoxicam
4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
Mobiflex
Tenoxicam
Tenoxicamum
Octiveran
4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide1,1-Dioxide
4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno2,3-e1,2thiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
2H-thieno2,3-e-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide
Tilcotil
2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide
Liman
Novo-Tenoxicam
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Tenoxicam suppliers

Price: $132/10mM*1mLinDMSO

Reference only. check more Tenoxicam price

Related Compounds: More...
Tenoxicam Impurity 1
504-29-0
TenoxicaM IMpurity D (N-Methyl-N'-(2-pyridyl)oxaMide)
52781-01-8
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
5-chloro-N-(1-(furan-2-carbonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2-nitrobenzamide
941900-61-4
2-((1-(2-(4-methylpiperidin-1-yl)-2-oxoethyl)-1H-indol-3-yl)sulfonyl)-N-phenethylacetamide
878060-46-9
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
tert-Butyl-DL-alanine
1375289-11-4
Chemsrc provides Tenoxicam(CAS#:59804-37-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Tenoxicam are included as well.>> amp version: Tenoxicam

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved